Unlock the White House Watch newsletter for free
Your guide to what Trump’s second term means for Washington, business, and the world
Donald Trump is taking bold steps to address the rising cost of prescription drugs in the United States. Despite facing opposition from the pharmaceutical industry and some senior Republicans, Trump announced on social media that he plans to sign an executive order that will slash drug prices by 30 to 80 percent.
In his announcement, Trump revealed his intention to implement a “most favored nation” policy, which would ensure that the US pays the same price for medications as the nation with the lowest price globally. This move echoes a similar attempt made during Trump’s first term, which was met with strong resistance from pharmaceutical companies.
Undeterred by opposition, Trump expressed his determination to push through the executive order, emphasizing that campaign contributions will not influence his decision-making. He stated on Truth Social, “We are going to do the right thing, something that the Democrats have fought for many years.”
In response to Trump’s proposal, industry lobby group PhRMA criticized the idea of government price-setting, arguing that it would harm American patients. The group suggested that addressing the role of middlemen in the healthcare system would be a more effective way to lower drug costs.
During Biden’s tenure, a drug negotiation provision was included in the Inflation Reduction Act, targeting specific medicines and estimated to save nearly $100 billion over a decade. This move led to legal challenges from pharmaceutical companies, who argued that such measures stifle innovation and research funding.
Trump dismissed these claims, asserting that drug companies have unfairly shifted the burden of research and development costs onto American consumers. He believes that his executive order will finally bring fairness to the pricing of medications in the US.
Efforts to include a drug price reduction provision in a forthcoming budget bill have faced resistance from some senior Republicans, including House Speaker Mike Johnson. Despite these challenges, Trump remains committed to his goal of making prescription drugs more affordable for all Americans.
As the debate over drug pricing continues to unfold, stay informed with the White House Watch newsletter, your trusted source for insights into the impact of Trump’s policies on Washington, business, and the global landscape. Subscribe now to unlock exclusive content and stay ahead of the latest developments.
